RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
here’s another article discussing the potential for a vaccine in order to allow people to return to, as you put it, doing what they want. https://t.co/7LCnexbKB2
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
RT @DrJenGunter: We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot…
We still don't understand enough about immunity and coronavirus, so lots of vaccine targets to be tested. Basically, a lot of trial and error. This is a summary of targets from a recent study of a vaccine candidate. 3/ https://t.co/10pyQglsDW https://t.co/
RT @maya_goldenberg: This is the ONLY published COVID-19 vaccine trial. Phase 1 trial, mixed results 2/3 https://t.co/VLPO91vgxi
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @maya_goldenberg: This is the ONLY published COVID-19 vaccine trial. Phase 1 trial, mixed results 2/3 https://t.co/VLPO91vgxi
This is the ONLY published COVID-19 vaccine trial. Phase 1 trial, mixed results 2/3 https://t.co/VLPO91vgxi
Aici e studiul chinezilor. https://t.co/xb9lCpkGqW
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
RT @drsanjaygupta: A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact,…
A lot of our enthusiasm around vaccines and therapeutics for #COVID19 has come solely from press statements. In fact, there is only one published study of a Covid-19 vaccine candidate in humans, which comes from China. (7/19) https://t.co/l9l00TdXdP
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/B0DjIn00FD
RT @ChineseEmbinUS: The first to reach phase 1 clinical trial, China's COVID-19 vaccine has been found to be safe, well-tolerated, and able…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/xAabUwuHac
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Is the Ad5 vectored #COVID19 #vaccine candidate safe, tolerable, and effective? The study published by the #Lancet and summarized below is the first in-human trial of a COVID-19 vaccine. #MedTwitter https://t.co/LaMvj5Osww https://t.co/vy49fWIy44
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial ... but experience from other diseases may caution the optimism yet... https://t.co
Great work from our Vice President @medicalwomenuk
@BidoliNicola @uacjess @flavinkins I am trying to find updated news if you can't: 1. https://t.co/fLMBo7iXry have a look to see if you can find specific evidence that her team is still at WIV: https://t.co/PclzL5hK3E you may be right but needs updated evid
RT @profchloeorkin: 1st published COVID-19 vaccine trial in humans in the @lancet : -Ad5 vaccine safe & (modestly) immunogenic, moves phase…
RT @profchloeorkin: 1st published COVID-19 vaccine trial in humans in the @lancet : -Ad5 vaccine safe & (modestly) immunogenic, moves phase…
RT @profchloeorkin: 1st published COVID-19 vaccine trial in humans in the @lancet : -Ad5 vaccine safe & (modestly) immunogenic, moves phase…
1st published COVID-19 vaccine trial in humans in the @lancet : -Ad5 vaccine safe & (modestly) immunogenic, moves phase II -However use of Ad5 vector concerning ...in HIV vac trials, pre-existing immunity assoc w’ HIV acquisition. https://t.co/63UtAB
RT @TommyTopic: El hallazgo de una potencial vacuna, segura, bien tolerada, desarrollada en Wuhan, China, es publicadl por el prestigioso L…
ECA Fase I => Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-In-Human Trial https://t.co/ILCGPnaLCU
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
@genevievducauze @ArianeWalter @reseau_internat 50 vaccins ARN sont en développement CanSino Biologics a publié des résultats dont il,ressort une efficacité d'environ 50% du vaccin, moindre sur les personnes les plus âgées, et avec des effets secondaires s
Thanks to Aneesh Sharma for a great journal club presentation yesterday on a trial of a recombinant adenovirus type-5 vectored COVID-19 vaccine: https://t.co/RJRiG2vASr
RT @akelvinlab: Hi everyone! Please join me tonight 9 pm EDT for the @IDJClub discussion of the CanSino adenovirus type-5 (Ad5) vectored CO…
RT @BcnVih: #PapersOnFire📄🌍 con la Dra. @NuriaCliment1 @TheLancet publica el 1r ensayo en humanos de una #vacuna para #COVID19 siendo cap…
Hoy en #ClubdelecturaIT discutiremos los resultados de fase I de la vacuna #CanSino, que completó sus primeros estudios en humanos. El artículo fué publicado el pasado 22 de mayo en la revista @TheLancet: https://t.co/imoRfj5IhT
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
RT @jahirschfieldmd: @ScottGottliebMD AR's (SAR's?): elevated liver enzymes, severe fever, fatigue, shortness of breath, hyperglycemia, mya…
Sars 2 Information https://t.co/1F2iJcPquv
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
RT @_VineetVashist: Fingers crossed! https://t.co/5HvUbsposr
@first78 نعم وها هو.. لاحظ الكم الهائل من التفاصيل.. طريقة فحص.. طريقة تصميم التجربة.. كم شخص https://t.co/C23DuDEeqA
It would have been helpful if #Sinovac defined 'neutralizing antibody seroconversion'. E.g. in the Chinese Ad5 phase I Lancet paper, it was defined as >4x increase from baseline. W/out high Ad5 pre-existing antibodies that reached 85% in high-dose gro
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet 新型コロナウイルスのワクチン試験 第1相試験 非盲検 非ランダム 人では初? https://t.co/Yr1OJFMaOZ
RT @cczielinski: Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID…
Great news and paving the way: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID-19 #vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/3tTqwP2MU7
多分ですが、これが該当記事 Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/S9aL3QLWfQ
😷 [Articles] Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial 👉 https://t.co/WwjWJuURLu 💊 #Medical #GroupZirigoza
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/m9mZejTXRJ
[Articles] Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/09EesN2ZYY
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored #COVID-19 #vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/5GWesnvugK
[L’étude à découvrir] 22/05 > Innocuité, tolérabilité et immunogénicité d'un vaccin #CoVid19 vectorisé à adénovirus recombinant de type 5 : essai ouvert, non randomisé, de première échelle chez l'humain https://t.co/mp2UkXoDMa via @TheLancet #LaMethSci
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. https://t.co/g2xGWdY59p
RT @alishehri1400: #الموجة_الثانية #كورونا 🔴هل سيقدّرالله أن تكون بدايةانفراج هذه الغمّةمن #الصين كمابدأت منها؟ ✔الله أعلم؛ 📃بعدظهور نتائج…
RT @jahirschfieldmd: @ScottGottliebMD AR's (SAR's?): elevated liver enzymes, severe fever, fatigue, shortness of breath, hyperglycemia, mya…
RT @jahirschfieldmd: @ScottGottliebMD AR's (SAR's?): elevated liver enzymes, severe fever, fatigue, shortness of breath, hyperglycemia, mya…
RT @jahirschfieldmd: @ScottGottliebMD AR's (SAR's?): elevated liver enzymes, severe fever, fatigue, shortness of breath, hyperglycemia, mya…
RT @paulhunghk1001: #BREAKING 🚨@LANCET HAD BEEN CORRUPTED BY #CCP🚨 "At least one adverse reaction is reported in 75%-83% participants❗️"😱…
Soooooo Get a vaccine that causes side effects that are worse than if you get the disease, in 99%+ of the population?! #NoThanks
RT @jahirschfieldmd: @ScottGottliebMD AR's (SAR's?): elevated liver enzymes, severe fever, fatigue, shortness of breath, hyperglycemia, mya…
RT @jahirschfieldmd: @ScottGottliebMD AR's (SAR's?): elevated liver enzymes, severe fever, fatigue, shortness of breath, hyperglycemia, mya…
Sars 2 Anti https://t.co/1F2iJcPquv
#الموجة_الثانية #كورونا 🔴هل سيقدّرالله أن تكون بدايةانفراج هذه الغمّةمن #الصين كمابدأت منها؟ ✔الله أعلم؛ 📃بعدظهور نتائج مبشرةفي المرحلةالأولى؛بدأت المرحلةالثانية لدراسة #لقاح_كورونا(#كوفيد١٩) 🌹يبقى اللجوءإلى الله ثم اتباع التعليمات أهم أسباب الوقاية🌹 http
RT @JenniferSpicer4: Everyone join tonight!